Under the Microscope: Tumor Invasion Grading Predicts Survival After Liver Cancer Conversion Therapy

For patients diagnosed with hepatocellular carcinoma (HCC), the most common form of primary liver cancer, the word unresectable has historically been a devastating one. When tumors are too large, too numerous, or positioned too dangerously within the liver to be removed surgically, the standard options shrink dramatically. In recent years, however, a strategy known as conversion therapy has begun to change that calculus. By treating patients with drug combinations before surgery, oncologists have found that some initially unresectable tumors shrink enough to make curative hepatectomy possible. A new multicenter study published in BMC Cancer now adds a crucial layer of nuance to this evolving field, showing that the microscopic fingerprint a tumor leaves behind after such treatment can predict, with striking precision, which patients will remain cancer-free and which will relapse.

The study, led by Shichuan Tang, Tingfeng Huang, and colleagues at the Mengchao Hepatobiliary Hospital of Fujian Medical University and collaborating institutions across China, focused on a pathological feature called microvascular invasion, or MVI. MVI refers to the presence of tumor cell clusters within small blood vessels in the liver tissue surrounding the main tumor mass. It is a subtle phenomenon, invisible on imaging scans and detectable only when a pathologist examines the resected specimen under a microscope. Yet its clinical significance is enormous: MVI is widely regarded as one of the strongest predictors of early recurrence after liver cancer surgery, because tumor cells that have already entered the vasculature are, in effect, seeds that may have scattered throughout the liver before the operation even began.

What makes the new research particularly timely is its patient population. All 101 individuals in the study had initially unresectable hepatocellular carcinoma and underwent hepatectomy only after receiving conversion therapy consisting of tyrosine kinase inhibitors (TKIs) combined with anti-PD-1 antibodies. TKIs are oral targeted drugs that interfere with signaling pathways driving tumor growth and angiogenesis, while anti-PD-1 antibodies are immune checkpoint inhibitors that release the molecular brakes on T cells, allowing the immune system to attack cancer cells. This combination has rapidly become one of the most widely used conversion regimens worldwide, but a key question has lingered: once these drugs have transformed an inoperable tumor into an operable one, what determines the patient’s long-term fate?

To answer that question, the research team applied a severity grading system for MVI that divides patients into three categories. Patients in the M0 group showed no microvascular invasion at all. Those in the M1 group had between one and five MVI foci located within one centimeter of the tumor. The M2 group, the most severe category, included patients with more than five foci within one centimeter of the tumor and/or any invasive foci found more than one centimeter away, a finding indicating that tumor cells had traveled further into the surrounding liver. This graded approach goes beyond the simple binary question of whether invasion is present or absent, capturing instead a spectrum of biological aggressiveness.

The distribution of patients across these categories was itself informative. Of the 101 patients, 62 fell into the M0 group, 21 into M1, and 18 into M2, meaning that nearly four in ten patients who achieved successful conversion therapy still harbored microscopic evidence of vascular spread. The researchers then tracked two critical endpoints: recurrence-free survival (RFS), which measures how long patients remain free of detectable cancer after surgery, and overall survival (OS), which tracks how long patients live. The differences that emerged between the groups were dramatic and statistically significant.

At two years after surgery, the recurrence-free survival rate was 57.8 percent for patients with no microvascular invasion, 43.7 percent for those with mild invasion, and just 11.1 percent for those with severe invasion. Overall survival followed a similarly sobering gradient: 92.9 percent at two years for the M0 group, 84.7 percent for the M1 group, and only 40.1 percent for the M2 group. In other words, a patient whose resected specimen showed extensive microscopic vascular invasion was roughly four times more likely to have died within two years than a patient whose specimen was clean, despite both having undergone the same operation after the same class of drug therapy.

To ensure these associations were not confounded by other clinical variables, the team performed multivariable analyses, statistical models that adjust for competing risk factors. The results confirmed the independent prognostic power of MVI grading. Compared with the M0 group, patients in the M1 category had a 1.81-fold higher risk of recurrence (hazard ratio 1.81, 95 percent confidence interval 1.17 to 2.11), while those in the M2 category faced a 3.98-fold higher risk (95 percent confidence interval 1.91 to 8.29). The survival gap was even starker: M1 status carried a 3.57-fold higher risk of death (95 percent confidence interval 1.05 to 13.33), and M2 status a 12.22-fold higher risk (95 percent confidence interval 3.87 to 38.61). These hazard ratios, all statistically significant, establish MVI severity as one of the dominant determinants of outcome in this population.

The biological story behind these numbers is worth unpacking. Conversion therapy with TKIs and anti-PD-1 antibodies can produce remarkable shrinkage of the visible tumor, sometimes to the point where surgeons can achieve what appears to be a complete resection with clear margins. But the drugs act primarily on the main tumor mass and its immediate microenvironment. Tumor cell nests that have already detached into small portal or hepatic venules may be less susceptible to the same immune attack, shielded within vascular spaces or already lodged in distant liver parenchyma. The graded MVI system effectively measures how far this occult dissemination has progressed. A few foci close to the tumor suggest early, limited spread; numerous foci or foci beyond one centimeter suggest a tumor that has been seeding the liver more aggressively, even while responding to therapy on the surface.

The clinical implications of the study are substantial. Postoperative management of converted HCC patients has long been a gray zone: some patients receive adjuvant therapy, others undergo intensified surveillance, and the decision-making has often rested on tumor size, number, and response to preoperative treatment rather than on pathology of the resected specimen. The new findings suggest that MVI grading should become a central pillar of postoperative risk stratification. A patient classified as M0 might be counseled that their two-year survival odds exceed 90 percent and could potentially be spared intensive adjuvant regimens, whereas an M2 patient, with a two-year survival rate of roughly 40 percent, would be an obvious candidate for aggressive adjuvant treatment, close-interval imaging surveillance, and enrollment in clinical trials of postoperative immunotherapy.

Several caveats deserve mention. The study involved 101 patients drawn from a multicenter database, a respectable but ultimately modest sample size, and the wide confidence intervals around some of the survival hazard ratios reflect the limited number of events in the smaller M1 and M2 groups. The analysis was retrospective in design, and the grading of MVI, while standardized, depends on the thoroughness of pathological sampling of the resected specimen. Nonetheless, the consistency of the signal across both recurrence and survival endpoints, and its persistence after multivariable adjustment, lends considerable weight to the conclusion. As conversion therapy with TKIs and anti-PD-1 antibodies continues to expand globally, offering curative surgery to patients who once had no surgical option, this study provides a practical, pathology-based compass for navigating what comes after the operation. The message is clear: even after the most successful drug-induced transformation, the microscope still holds the final word on a patient’s prognosis.

Subject of Research: Severity grading of microvascular invasion as a prognostic marker after conversion therapy and hepatectomy for unresectable hepatocellular carcinoma

Article Title: Severity grading of microvascular invasion predicts oncological outcomes following hepatectomy for unresectable hepatocellular carcinoma converted by tyrosine kinase inhibitors plus anti-PD-1 antibodies

Article References: Tang, S., Huang, T., Zheng, X., Cui, Z., Liu, D., Peng, S., Kong, J., Luo, C., Fan, R., Guo, L., Zhang, K., Lin, Q., Fu, J., Zheng, L., & Zeng, Y. (2026). Severity grading of microvascular invasion predicts oncological outcomes following hepatectomy for unresectable hepatocellular carcinoma converted by tyrosine kinase inhibitors plus anti-PD-1 antibodies. BMC Cancer. https://doi.org/10.1186/s12885-026-17057-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17057-0

Keywords: hepatocellular carcinoma, microvascular invasion, conversion therapy, tyrosine kinase inhibitors, anti-PD-1 antibodies, hepatectomy, recurrence-free survival, overall survival, prognosis, liver cancer, immunotherapy, risk stratification